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Abstract
Background: Patients starting antiretroviral therapy (ART) for acquired immunodeficiency syndrome (AIDS) in sub-Saharan
Africa have high rates of mortality in the initial weeks of treatment. We assessed the association of serum phosphate with
early mortality among HIV-infected adults with severe malnutrition and/or advanced immunosuppression.
Methodology/Principal Findings: An observational cohort of 142 HIV-infected adults initiating ART in Lusaka, Zambia with
body mass index (BMI) ,16 kg/m
2 or CD4
+ lymphocyte count ,50 cells/mL, or both, was followed prospectively during the
first 12 weeks of ART. Detailed health and dietary intake history, review of systems, physical examination, serum metabolic
panel including phosphate, and serum ferritin and high-sensitivity C-reactive protein (hsCRP) were monitored. The primary
outcome was mortality. Baseline serum phosphate was a significant predictor of mortality; participants alive at 12 weeks
had a median value of 1.30 mmol/L (interquartile range [IQR]: 1.04, 1.43), compared to 1.06 mmol/L (IQR: 0.89, 1.27) among
those who died (p,0.01). Each 0.1 mmol/L increase in baseline phosphate was associated with an incremental decrease in
mortality (AHR 0.83; 95% CI 0.72 to 0.95). The association was independent of other metabolic parameters and known risk
factors for early ART-associated mortality in sub-Saharan Africa. While participant attrition represented a limitation, it was
consistent with local program experience.
Conclusions/Significance: Low serum phosphate at ART initiation was an independent predictor of early mortality among
HIV patients starting ART with severe malnutrition or advanced immunosuppression. This may represent a physiologic
phenomenon similar to refeeding syndrome, and may lead to therapeutic interventions that could reduce mortality.
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Introduction
Access to antiretroviral therapy (ART) for acquired immuno-
deficiency syndrome (AIDS) in sub-Saharan Africa has expanded
rapidly since 2003, but mortality, especially in the first month after
initiating treatment, remains high [1,2,3]. The etiology is likely
multifactorial, but several analyses from the region have identified
low body mass index (BMI) and low CD4
+ lymphocyte count as
powerful predictors of death shortly after starting ART [4,5,6,7].
HIV-associated wasting, defined as a 10% or greater decrease
from usual body weight, with concomitant chronic diarrhea or
chronic weakness and fever, was recognized as a significant
prognostic factor in HIV infection early in the epidemic [8,9]. In
areas where food is scarce, wasting may be accelerated by
unbalanced or inadequate energy intake, leading to multiple
metabolic abnormalities rarely seen in resource-rich settings.
Rapid weight loss or prolonged fasting can deplete serum
phosphate stores, leading to a state of hypophosphatemia and
the potential for refeeding syndrome to develop upon increased
nutrient intake [10]. This potentially lethal condition is classically
defined by electrolyte and fluid shifts following a reversal from
catabolism and fat oxidation to the metabolism of exogenous
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and neurologic sequelae, among others [12,13]. Rapid improve-
ments in appetite and activity level reported by patients starting
ART in sub-Saharan Africa, [14,15] where dietary staples are
often high in carbohydrate (e.g., maize meal and green banana)
[16,17], could conspire to produce a refeeding-like syndrome,
especially in patients with severe wasting.
We hypothesized that metabolic abnormalities at the intersec-
tion of advanced HIV disease and malnutrition are transiently
exacerbated by the introduction of ART and could explain some
of the excess early mortality observed in developing countries.
Among these could be the refeeding syndrome or a variant of it.
We conducted a prospective cohort study to assess the association
of serum phosphate levels with early mortality among HIV-
infected individuals with severe malnutrition and/or advanced
immunosuppression in Lusaka, Zambia.
Materials and Methods
Setting
This study enrolled HIV-infected adults initiating ART in a
public sector primary care clinic located in the Chawama
neighborhood of Lusaka, Zambia. Chawama is a high-density
residential area with an estimated population of 56,300 in 2000
[18]. The neighborhood encompasses a range of housing, from
planned developments of modern units connected to municipal
electricity, water, and sewer systems to crowded, unplanned
developments of mud or concrete block structures without
electrification. The ART program at Chawama clinic began in
March 2006 as part of the Zambian national program for HIV
care and treatment [3,19]. When our study enrollment began in
November 2006, 1539 patients were enrolled in care at Chawama
clinic and 874 were receiving ART.
Study outcomes
The primary study endpoint was all-cause mortality in the first
12 weeks of ART. Baseline phosphate concentration was the main
exposure variable. Serum phosphate, dietary intake, and calculat-
ed energy intake at one week were secondary outcomes, in
addition to receipt of phosphate supplementation at any time
during the study.
Eligibility criteria
Individuals were eligible for the study if they qualified for ART
according to national guidelines in place at the time (i.e., WHO
stage 4 disease, a CD4
+ lymphocyte count ,200 cells/mL, or
WHO stage 3 disease and a CD4
+ lymphocyte count ,350 cells/
mL) and were intending to start therapy the same day; had a
BMI,16 kg/m
2 or a CD4
+ lymphocyte count ,50 cells/mL;
intended to remain in the area for the duration of study; agreed to
adhere to the additional study visits and laboratory testing
requirements; and agreed to be contacted in the event of a missed
study visit.
Study design and procedures
Individuals who met the study eligibility criteria and provided
written informed consent were enrolled on the day of ART
initiation. At each study visit, participants were evaluated by a
research nurse and a clinical officer (similar to a physician assistant
in the US and Europe), and additional evaluation was performed
by a supervising physician as needed. The initial visit included a
detailed health and 24-hour dietary intake history, review of
systems, physical examination, and laboratory testing (serum
metabolic panel including phosphate, and serum ferritin and high-
sensitivity C-reactive protein (hsCRP)). The first-line ART
regimen was selected from the national program formulary: a
non-nucleoside reverse transcriptase inhibitor (NNRTI; efavirenz
[EFV] or nevirapine [NVP]), in combination with two nucleoside
reverse transcriptase inhibitors (NRTIs; lamivudine [3TC] with
either zidovudine [ZDV] or stavudine [d4T]). In July 2007,
tenofovir with emtricitabine (TDF/FTC) was introduced as the
first line NRTI combination by the national program, and study
participants enrolled after this time received the new agents [20].
Patients on treatment prior to July 2007 remained on the original
regimen, except in cases of treatment failure or toxicity.
Subsequent study visits occurred after 1, 2, 4, 8, and 12 weeks of
ART. At each visit, the symptom assessment, physical examina-
tion, and metabolic panel were repeated; 24-hour dietary intake
recall was repeated after 1, 4, and 12 weeks. Nutrient intake was
computed using Nutrition Data System for Research (NDS-RH,
Minneapolis, Minnesota, USA; www.ncc.umn.edu). Using the
2005 Zambian Nutrition Commission composition data [21], we
matched consumed foods to the NDS-R database food and
nutrient content and added recipes of frequently consumed foods
to the database. Zambian foods not in the database were
substituted with similar foods in the database using recommended
tolerance guidelines.
When deficiencies of phosphate were detected, we intervened
according to a predetermined algorithm based on serum level.
Participants whose levels were 0.65–0.86 mmol/L were counseled
to increase their intake of phosphorus-containing foods and
provided a World Food Programme macronutrient supplement
ration; those whose levels were 0.5–0.64 mmol/L also received
oral phosphate supplementation, typically in 7-day allotments,
while those with levels ,0.5 mmol/L were additionally treated
with intravenous phosphate supplementation. Intervention typi-
cally occurred at least 7 days after the serum collection due to time
required for assay completion and reporting of results to the study
clinic.
If a participant missed a study visit, study staff first attempted to
contact the individual or a designated representative by mobile
phone. If the participant could not be contacted, community
outreach teams attempted to locate the patient or a relative using
housing locator forms completed at enrollment in HIV care [22].
If the participant could not be located or credible information on
vital status could not be obtained from relatives or the community,
the participant was classified as lost to follow-up.
The study protocol and informed consent documents were
approved by the University of Zambia Research Ethics Commit-
tee (Lusaka, Zambia), and the Institutional Review Boards at the
University of Alabama at Birmingham (Birmingham, Alabama,
USA) and Vanderbilt University (Nashville, Tennessee, USA).
Laboratory assays
CD4
+ lymphocyte counts were performed using a Beckman
Coulter Epics XL-MCL flow cytometer (Beckman Coulter, Inc.,
Fullerton, CA, USA), and hemogram or complete blood count
with differential using a Horiba ABX Pentra 80 (Horiba ABX
Diagnostics Inc., Montpellier, France). Routine and study-specific
chemistry assays were measured using a Roche COBAS Integra
400+ (Roche Diagnostics, Basel, Switzerland) or a Pointe 180
Chemistry Analyzer (Pointe Scientific, Canton, MI, USA).
Statistical methods
We compared differences between survivors and non-survivors
with the Wilcoxon rank sum test for continuous variables and the
chi-square test for categorical variables. We used Cox proportional
hazards regression to determine whether baseline phosphate
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potential confounders: sex, age, and baseline hemoglobin [23,24].
We modeled the relationship between the log-hazard of death and
baseline phosphate by first assuming linearity (primary analysis)
and then relaxing this assumption using restricted cubic splines
with 3 knots. Linearity was assessed using a likelihood ratio test. In
the primary analysis, a participant was censored at the last study
visit date if vital status at 12 weeks was unknown (i.e., lost to follow-
up). A second multivariable regression modeled the relationship
between time to death or loss to follow-up and the same predictors.
We accounted for missing values of baseline variables with
multiple imputationtechniques[25].Inmultiple imputation,known
Figure 1. Study procedures and cohort status by study visit.
doi:10.1371/journal.pone.0010687.g001
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plausible values for those that are missing. We repeated this process
25 times and performed Cox proportional hazard regression on
each imputed data set, producing multiple analysis results. We
report the average estimates from these multiple calculations. R-
software 2.9.2 (www.r-project.org) was used for data analyses.
Results
Between 6 November 2006 and 12 November 2007, 142
participants were enrolled. Figure 1 describes the study visit
schedule and the status of the cohort at each visit. Thirty-two
(23%) participants met only the BMI criterion for participation, 83
(58%) met only the CD4
+ lymphocyte criterion, and 27 (19%) met
both. Twenty-five participants died over the 12-week follow-up
period (mortality rate 87.4 per 100 person-years of follow-up); 10
(40%) participants died within four weeks of starting ART,
although none died in the first week. Thirty-three participants
(23%) were lost to follow-up; the median follow-up time for those
lost was 58 days (interquartile range [IQR]: 45, 71).
Table 1 shows the baseline demographics of the cohort.
Participants were predominantly female (61%), consistent with
trendsseeninthe LusakaHIVcareprogram[3].ThemedianCD4
+
lymphocyte count (34 cells/mL) and BMI (16.4 kg/m
2) were low,
with narrow IQRs. There were no clinically meaningful differences
between sexes in BMI, CD4
+ lymphocyte count, hemoglobin, or
baseline median serum chemistries (data not shown). First-line ART
regimens differed significantly between the sexes: 25% of males
received efavirenz-containing regimens compared to 15% of
females, while 47% of males received zidovudine-containing
regimens compared to 18% of females (p,0.01).
We found no significant differences in baseline demographic
and medical descriptors, or serum chemistries, between partici-
pants alive at 12 weeks versus those lost to follow-up, with the
exception of age (Table 2). We also compared participants lost to
follow-up with those not lost to follow-up (i.e., known to be alive or
dead at 12 weeks) and found no significant differences in baseline
descriptors or serum chemistries, with the exception of age (30
versus 34 years; p,0.01) and serum glucose (3.6 versus 4.0 mmol/
L; p=0.03 [data not shown]).
Baseline serum phosphate was significantly higher among
participants alive at 12 weeks (median 1.30 mmol/L; IQR: 1.04,
1.43), compared to those who died (median 1.06 mmol/L; IQR:
0.89, 1.27; p,0.01). Other measured electrolytes were not
significantly associated with mortality (Table 2). Overall, 44 (31%)
participants had phosphate levels ,0.87 mmol/L at some point
during the study, and received at least dietary counseling. Seventeen
(12%) had levels ,0.65 mmol/L at some point, 7 (5%) of which
occurred on $2 visits despite phosphate supplementation. By week
12,7(8%)survivorscomparedto5(20%)deceasedparticipantsand1
(3%) lost participant had received phosphate supplementation orally
only(12persons)orintravenouslyandorally(1person)onatleastone
occasion. One participant met criteria for intravenous supplemen-
tation at week 4 (serum phosphate 0.47 mmol/L) but died 8 days
later without returning to the clinic. Of those supplemented, 5 (42%)
had baseline phosphate levels ,0.87 mmol/L; these participants’
median (IQR)timeto supplementation was14 (13,21) daysand their
median (IQR) duration on supplementation was 7 (7, 7) days.
Seven (58%) supplemented participants had baseline phosphate
levels $0.87 mmol/L but required supplementation after subse-
quent visits. These participants’ median (IQR) time to supplemen-
tation was 29 (20.5, 61) days and their median (IQR) duration on
supplementation was 6 (6, 7) days. Mortality didnot statistically differ
by phosphate supplementation (p=0.20).
At baseline there were no significant differences in appetite or
dietary intake of survivors compared to non-survivors (p.0.05).
However, after one week of ART, appetite and intakes of
carbohydrate and total energy were significantly lower in non-
survivors than in survivors (p,0.01).
After adjusting for sex, age, CD4
+ lymphocyte count, BMI, and
baseline hemoglobin, low baseline serum phosphate was associated
with an increased risk of death within 12 weeks of ART initiation
(p=0.008, Table 3). For each 0.1 mmol/L increase in baseline
phosphate, the estimated hazard of death decreased 17% (adjusted
hazard ratio (AHR) 0.83; 95% CI 0.72 to 0.95). BMI, CD4
+
lymphocyte count, and hemoglobin were not significant predictors
of mortality in this model. In secondary analyses that adjusted for
significant variables in Table 2 (i.e., albumin, ferritin, and hsCRP)
baseline phosphate remained a significant predictor of mortality
(p,0.05; data not shown).
There was insufficient evidence to conclude that the relationship
between baseline serum phosphate and the log-hazard of death
Table 1. Baseline participant characteristics.
N 142
Female, n (%) 87 (61%)
Age, median years (IQR) 32 (28, 38)
Weight, median kg (IQR) 45.5 (41, 51)
BMI, median kg/m
2 (IQR) 16.4 (15.4, 18.5)
CD4
+ count, median cells/mL (IQR) 34 (21, 47)
Hemoglobin, median g/dL (IQR) 9.8 (8.8, 11.6)
Serum chemistries, median (IQR) Reference
Range [31]
Phosphate, mmol/L 1.26 (1.03, 1.42) 0.81–1.4
Potassium, mmol/L 4.2 (3.7, 4.6) 3.5–5.0
Chloride, mmol/L 108 (103, 111) 102–109
Bicarbonate, mmol/L 29 (26, 31) 22–30
BUN, mmol/L 3.3 (2.4, 4.7) 2.5–7.1
Creatinine, mmol/L 71 (62, 88) 44–106*
Glucose (non-fasting), mmol/L 3.9 (3.4, 4.8) 4.2–6.1
Magnesium, mmol/L 0.88 (0.79, 0.96) 0.62–0.95
Albumin, g/L 29.5 (23.9, 33.2) 40–53*
Ferritin, mg/L 221 (59, 485) 10–248*
hsCRP, mg/L 2.75 (1.1, 15.2) 0.2–3.0
ART Regimen, n (%)
AZT/3TC/EFV 8 (5.6%)
AZT/3TC/NVP 34 (23.9%)
d4T/3TC/EFV 15 (10.6%)
d4T/3TC/NVP 62 (43.7%)
TDF/FTC/EFV 4 (2.8%)
TDF/FTC/NVP 19 (13.4%)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; BUN, blood
urea nitrogen; hsCRP, high sensitivity C-reactive protein; IQR, interquartile
range.
Among the 142 cases included in the multivariable analysis, values were
missing for the following measurements: 8 (6%) baseline serum phosphate, 31
(22%) week one serum phosphate, 29 (20%) baseline hemoglobin (because
either blood or assay reagents could not be obtained), 2 age (birth dates
unknown), and one BMI (participant could not stand for height measurement).
*Normal creatinine range: females 44–80, males 53–106 mmol/L; normal
albumin range: females 41–53, males 40–50 g/L; normal ferritin range: females
10–150, males 29–248 mg/L.
doi:10.1371/journal.pone.0010687.t001
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good predictor of mortality in secondary analyses that relaxed the
linearity assumption (p=0.05; data not shown). Baseline phos-
phate was not associated with an increased risk of death or loss to
follow-up (AHR=0.98 compared to patients who were active and
alive, 95% CI 0.90 to 1.06). While the absolute phosphate change
from baseline to week one trended toward statistical significance
(p=0.07), the percentage decrease (14.9% [alive] versus 9.0%
[deceased]) did not (p=0.21). Additionally, median week one
phosphate values did not differ significantly between alive (1.06)
and subsequently deceased (1.07) participants.
Discussion
In this observational cohort of HIV-infected persons with severe
malnutrition, advanced immunosuppression, or both, a low serum
phosphate at ART initiation predicted lower survival probability
at 12 weeks. The increased hazard of death conferred by low
serum phosphate was independent of other metabolic parameters,
hsCRP, and known risk factors for early ART-associated mortality
in sub-Saharan Africa, including low BMI, CD4
+ lymphocyte
count and hemoglobin.
Our findings may represent a variant of the refeeding syndrome
associated with advanced HIV disease, in which low pre-ART
serum phosphate is insufficient to maintain homeostasis in response
to metabolic changes accompanying treatment initiation. The
increased appetite and capacity for physical activity often reported
by patients starting ART could reflect a burst of phosphate-
dependent cellular respiration and ATP generation in response to
reduced systemic inflammation and HIV-1 viral replication[14,15].
This is but one speculative hypothesis for our findings, and further
research into the metabolic consequences of ART in advanced HIV
infection is warranted. The lowerappetite and dietary intakeamong
non-survivors after one week of ART may indicate overall
worsening of their condition and suggests that the phosphate-
mortality interaction did not strictly represent refeeding.
The lack of association between week one phosphate and
subsequent mortality suggests that acute electrolyte derangements
were not a proximate cause of death in most instances. However, 10
deaths (40%) occurred in the second through fourth weeks of ART.
This timing is consistent with reports of refeeding syndrome deaths
among starving prisonersliberated frominternment after WorldWar
II [26,27], but it could also be consistent with immune reconstitution
inflammatory syndrome (IRIS). At least one study participant
Table 2. Baseline participant characteristics by 90-day survival.
Alive (n=84) Dead (n=25) p * Lost (n=33) p **
Female, n (%) 53 (63%) 12 (48%) 0.26 22 (66.7%) 0.88
Age, median years (IQR) 34 (29, 38) 34 (29, 41) 0.72 30 (25, 32) ,0.01
Weight, median kg (IQR) 46 (41, 52) 42 (41, 48) 0.20 46 (40, 51) 0.84
BMI, median kg/m
2 (IQR) 16.5 (15.4, 18.6) 16.0 (15.2, 17.0) 0.30 16.7 (15.6, 19.2) 0.48
CD4
+ count, median cells/mL (IQR) 36 (22, 48) 31 (23, 45) 0.94 30 (20, 47) 0.51
Hemoglobin, median g/dL (IQR) 10.0 (8.9, 11.7) 9.3 (8.6, 11.1) 0.22 9.7 (8.2, 11.0) 0.20
Serum chemistries, median (IQR)
Phosphate, mmol/L 1.30 (1.04, 1.43) 1.06 (0.89, 1.27) ,0.01 1.28 (1.18, 1.50) 0.20
Potassium, mmol/L 4.2 (3.7, 4.6) 4.1 (3.5, 4.7) 0.52 4.1 (3.7, 4.5) 0.71
Chloride, mmol/L 108 (103, 110) 103 (97, 112) 0.25 109 (104, 112) 0.33
Bicarbonate, mmol/L 28.8 (25.4, 30.7) 28.1 (26.9, 31.9) 0.44 29.3 (26.5, 30.6) 0.60
BUN, mmol/L 3.3 (2.6, 4.4) 3.6 (2.2, 4.4) 1.00 3.6 (2.1, 4.8) 0.77
Creatinine, mmol/L 75.2 (59.7, 88.4) 88.4 (70.7, 106.1) 0.12 70.7 (61.9, 99.4) 0.86
Glucose, mmol/L 3.9 (3.4, 4.8) 4.8 (3.6, 6.1) 0.07 3.6 (3.3, 4.3) 0.07
Magnesium, mmol/L 0.86 (0.79, 0.97) 0.91 (0.73, 0.98) 0.87 0.89 (0.82, 0.94) 0.61
Albumin, g/L 30.4 (25.8, 33.1) 24.0 (19.9, 29.4) ,0.01 31.4 (22.7, 33.6) 0.65
Ferritin, mg/L 168 (56, 419) 521 (395, 1029) ,0.01 204 (98, 483) 0.42
hsCRP, mg/L 2.4 (1.1, 9.9) 14.5 (4.7, 23) 0.01 2.5 (1.0, 17.0) 0.52
Week 1 phosphate, mmol/L (IQR) 1.06 (0.94, 1.26) 1.07 (0.78, 1.16) 0.30 1.08 (0.91, 1.16) 0.86
Change in baseline to week 1 phosphate, mmol/L (IQR) 20.18 (20.35, 0.01) 20.08 (20.17, 0.12) 0.07 20.14 (20.55,0.08) 0.83
% Change in baseline to week 1 phosphate (IQR) 214.9% (226.9, 1.2) 29.0% (218.5, 10.9) 0.21 210.9% (236.5, 8.9) 0.82
Reported baseline energy intake, kcal/d (IQR) 1499 (1028, 1853) 1252 (858, 1724) 0.09 1549 (969, 1851) 0.57
Reported baseline carbohydrate intake, g/d (IQR) 203 (153, 283) 181 (123, 237) 0.26 204 (145, 257) 0.51
Reported week 1 energy intake, kcal/day (IQR) 1540 (1076, 1762) 939 (726, 1280) ,0.01 1201 (919, 1430) 0.05
Reported week 1 carbohydrate intake, g/d (IQR) 207 (151, 261) 151 (113, 196) ,0.01 180 (124, 216) 0.07
Abbreviations: BMI, body mass index; BUN, blood urea nitrogen; hsCRP, high sensitivity C-reactive protein; IQR, interquartile range.
*P-values refer to comparisons between participants dead and alive at 12 weeks.
**P-values refer to comparisons between participants lost to follow-up and alive at 12 weeks. We also compared participants lost to follow-up with those not lost to
follow-up (i.e., known to be alive or dead at 12 weeks) and found no significant differences in baseline descriptors or serum chemistries, with the exception of age (30
versus 34 years; p,0.01) and serum glucose (3.6 versus 4.0 mmol/L; p=0.03) [data not shown].
doi:10.1371/journal.pone.0010687.t002
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year-old male with severe hypophosphatemia developed anasarca
after 6 weeks of ART despite oral and intravenous phosphorus
supplementation.Itresolved after2 weeksoffurthersupplementation
and administration of a low-dose diuretic [28].
Baseline serum phosphate retained significance as a predictor of
survival independent of renal function, acid-base status, albumin,
ferritin and hsCRP. Significantly higher baseline levels of ferritin
and hsCRP, both markers of systemic inflammation, among non-
survivors may indicate a greater burden of undiagnosed
opportunistic infections or an exaggerated response to HIV-1
viremia. The presence or absence of occult co-infections could not
be adequately explored in this study because of limited diagnostic
capabilities in the study setting, which was representative of public-
sector clinics in Lusaka Zambia. Further prospective studies to
characterize the etiology and epidemiology of occult infections in
severely immunocompromised HIV-infected adults using ad-
vanced diagnostic modalities are needed to explore this.
Thirteen participants received phosphate supplementation
because of low serum levels. While supplementation was not
significantly associated with survival, we cannot conclude that it
had no effect without an appropriate comparison group. Rather,
because we were ethically obligated to provide supplementation to
all participants with low phosphate levels, supplementation was
essentially a marker for hypophosphatemia. To the extent that
supplementation may have reduced mortality, it would bias our
results toward the null hypothesis of observing no mortality
difference between those with low serum phosphate and those with
normal phosphate.
The observational design of our study prevents us from
concluding a causal relationship between low serum phosphate
and mortality. The study was also limited by participant attrition,
but the number of lost participants was not atypical. The observed
loss rates are similar to reports from other programmatic cohorts
in sub-Saharan Africa, and previous analyses of the Zambian ART
program have reported a similar lost to follow-up rate prior to 6
months among low BMI patients [29,30]. Except for slight
differences in median age and serum glucose, those who were lost
to follow-up did not differ substantially when compared to either
survivors or all participants not lost to follow-up.
Relative homogeneity of known markers of advanced HIV
among study participants, indicated by narrow interquartile ranges
(Table 1), likely contributed to the finding that BMI, CD4+ count,
and hemoglobin were not significant predictors of mortality. The
independence of baseline serum phosphate as a predictor of
mortality is bolstered by our study inclusion criteria, which limited
the potential impact of known confounders.
In this observational cohort study, serum phosphate at ART
initiation was an independent predictor of mortality among patients
with advanced HIV disease. This may represent a physiologic
phenomenon similar to the refeeding syndrome. A randomized
prospective trial of phosphate repletion among patients with low
BMIs or low serum levels, either through electrolyte or nutritional
supplementation, is warranted to address causality and explore the
therapeutic implications of these findings.
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